For a study, researchers sought to describe trends in COVID-19 STEMI patients throughout the duration of the pandemic.

The NACMI (North American COVID-19 STEMI) registry is a multicenter, prospective, investigator-initiated registry of hospitalized STEMI patients in North America with confirmed or suspected COVID-19 infection. They evaluated changes in clinical features, treatment, and outcomes across patients treated in the first and second years of the pandemic (January 2020 to December 2020) vs. those treated in the second year (January 2021 to December 2021).

The current study comprised 586 COVID-19-positive STEMI patients, 227 of whom were treated in Y2020 and 359 in Y2021. The features of the patients varied throughout time. In Y2021, the proportion of Caucasian patients was higher (58% vs. 39%; P<0.001), patients presented with more typical ischemic symptoms (59% vs. 51%; P=0.04), and patients were less likely to have a shock (13% vs. 18%; P=0.07) or pulmonary manifestations (33% vs. 47%; P=0.001). In-hospital mortality reduced from 33% in 2020 to 23% in 2021 (P=0.008). In Y2021, none of the 22 vaccinated individuals died in the hospital, but 37 (22%) unvaccinated patients died in the hospital (P=0.009).

During the pandemic, there have been significant changes in the clinical features and outcomes of STEMI patients with COVID-19 infection.